European journal of ophthalmology · 2016
Multifocal corneal ablation (Supracor) in hyperopic presbyopia: 1-year results in a cross-sectional study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Schlote Torsten, Heuberger Alexander
Аннотация
PURPOSE: To evaluate the efficacy and safety of the multifocal excimer laser corneal ablation profile (the Supracor procedure) in hyperopic presbyopia 1 year after laser treatment.
METHODS: This prospective, consecutive, one-center, cross-sectional study included 20 patients with hyperopic presbyopia 1 year after treatment with the Supracor procedure. The main outcome measures were monocular uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA), photopic contrast sensitivity (Pelli-Robson charts), patient satisfaction, and functioning at 12 months.
RESULTS: Thirty-nine eyes of 20 patients (mean age 59 ± 7.2 years) were treated. Mean UDVA improved from 0.56 ± 0.31 (mean 0.34 logMAR) preoperatively to 0.9 ± 0.15 (mean 0.06 logMAR) 12 months after surgery. Mean UNVA increased from 0.15 ± 0.07 (mean 0.84 logMAR) before surgery to 0.62 ± 0.24 (mean 0.23 logMAR) 12 months after treatment. Four eyes lost 2 lines of corrected distance visual acuity (10.3%). Monocular photopic contrast sensitivity was within age-correlated normal range (Pelli-Robson chart, mean contrast sensitivity 1.83 ± 0.18). A total of 75% of the patients would undergo Supracor again (1 not, 4 perhaps). The most frequently reported side effects were increased glare, reduced distance vision, and fluctuations in vision. Most patients used artificial tears.
CONCLUSIONS: One year after Supracor, UDVA and UNVA improved markedly, photopic contrast sensitivity was in normal age-correlated range, and the majority of patients (75%) was satisfied with the results. Side effects like loss of distance vision, fluctuations of vision, and increased glare have a greater influence on patient satisfaction than the improvement of spectacle-free near vision.
METHODS: This prospective, consecutive, one-center, cross-sectional study included 20 patients with hyperopic presbyopia 1 year after treatment with the Supracor procedure. The main outcome measures were monocular uncorrected distance visual acuity (UDVA) and uncorrected near visual acuity (UNVA), photopic contrast sensitivity (Pelli-Robson charts), patient satisfaction, and functioning at 12 months.
RESULTS: Thirty-nine eyes of 20 patients (mean age 59 ± 7.2 years) were treated. Mean UDVA improved from 0.56 ± 0.31 (mean 0.34 logMAR) preoperatively to 0.9 ± 0.15 (mean 0.06 logMAR) 12 months after surgery. Mean UNVA increased from 0.15 ± 0.07 (mean 0.84 logMAR) before surgery to 0.62 ± 0.24 (mean 0.23 logMAR) 12 months after treatment. Four eyes lost 2 lines of corrected distance visual acuity (10.3%). Monocular photopic contrast sensitivity was within age-correlated normal range (Pelli-Robson chart, mean contrast sensitivity 1.83 ± 0.18). A total of 75% of the patients would undergo Supracor again (1 not, 4 perhaps). The most frequently reported side effects were increased glare, reduced distance vision, and fluctuations in vision. Most patients used artificial tears.
CONCLUSIONS: One year after Supracor, UDVA and UNVA improved markedly, photopic contrast sensitivity was in normal age-correlated range, and the majority of patients (75%) was satisfied with the results. Side effects like loss of distance vision, fluctuations of vision, and increased glare have a greater influence on patient satisfaction than the improvement of spectacle-free near vision.